XEPI Drug Patent Profile

When do Xepi patents expire, and what generic alternatives are available?

Xepi is a drug marketed by Lnhc and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-three countries.

The generic ingredient in XEPI is ozenoxacin. There is one drug master file entry for this compound. Additional details are available on the ozenoxacin profile page.

DrugPatentWatch^® Generic Entry Outlook for Xepi

Xepi was eligible for patent challenges on December 11, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 29, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XEPI

International Patents:	37
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	192
What excipients (inactive ingredients) are in XEPI?	XEPI excipients list
DailyMed Link:	XEPI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XEPI

NDA:

208945

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XEPI

XEPI is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No			Y

Expired US Patents for XEPI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017

International Patents for XEPI

When does loss-of-exclusivity occur for XEPI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Japan

Mexico

Netherlands

Philippines

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XEPI around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2344130
European Patent Office	1070713	DERIVES D'ACIDE QUINOLONECARBOXYLIQUE OU SELS DE CEUX-CI (QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF)
Chile	2015002899
China	1299356
Portugal	1070713
South Korea	20110071086	PHARMACEUTICAL TOPICAL COMPOSITIONS
Australia	2009305360

Supplementary Protection Certificates for XEPI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2344130	2017C/031	Belgium		PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519
2344130	132017000093887	Italy		PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711
2344130	300884	Netherlands		PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519
2344130	2017/038	Ireland		PRODUCT NAME: OZENOXACIN; NAT REGISTRATION NO/DATE: PA1744/003/001 20170616; FIRST REGISTRATION NO/DATE: ES/H/414/01/DC 20170519
2344130	C201730036	Spain		PRODUCT NAME: OZENOXACINO; NATIONAL AUTHORISATION NUMBER: 82357-ES/H/0414/001/DC; DATE OF AUTHORISATION: 20170830; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): ES/H/414/01/DC; DATE OF FIRST AUTHORISATION IN EEA: 20170519
2344130	122017000073	Germany		PRODUCT NAME: OZENOXACIN; NAT. REGISTRATION NO/DATE: 97303.00.00 20170803; FIRST REGISTRATION: BELGIEN BE509591 20170517
2344130	1790031-7	Sweden		PRODUCT NAME: OZENOXACIN; NAT. REG. NO/DATE: 54608 20170622; FIRST REG.: BE ES/H/414/01/DC 20170519

XEPI Market Analysis and Financial Projection

Last updated: April 24, 2026

XEPI: Market Dynamics and Financial Trajectory

XEPI (firdapse; brand spelling “XEPI”) operates in a narrow, high-specificity segment: treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults who have the disorder. The financial trajectory is driven by (1) regulatory durability in the US, (2) prescriber concentration in neuromuscular specialty care, (3) payer coverage limits for symptomatic neurostimulants, and (4) competition dynamics from legacy and off-label neuromuscular therapies.

What follows is the market structure and the financial path implied by US commercialization coverage, pricing/payer constructs, and post-launch sales execution in a small addressable market.

---

What is XEPI’s market position?

Therapy area and use constraints

• Indication: Lambert-Eaton myasthenic syndrome (LEMS) in adults (diagnosis is uncommon and requires neurologist-led pathways).
• Treatment type: symptomatic therapy, not curative; this matters because payer decisions tend to hinge on demonstrable clinical benefit and tolerability rather than disease modification.

Implication for commercial trajectory: XEPI’s ceiling is largely set by the diagnosed adult LEMS population and the portion of patients who meet reimbursement requirements and remain on therapy long-term.

Customer profile and channel structure

• Buyers are dominated by US specialty pharmacy networks and neuromuscular prescribers.
• Decision cycles are typically driven by:
  • neurologist diagnosis confirmation,
  • prior authorization and medical-necessity review,
  • ongoing safety monitoring for neurostimulant-class adverse events.

Demand concentration risk

In rare diseases and niche neuromuscular indications, sales volatility often comes from:

• diagnosis throughput (new patient identification),
• retention and persistence rates,
• formulary inclusions and restrictions.

Implication for financial trajectory: XEPI’s revenue growth profile depends less on broad consumer expansion and more on incremental diagnostic and access gains.

---

How do market dynamics shape sales growth?

1) Access and reimbursement mechanics

For niche specialty products like XEPI, the growth lever is not “pricing alone.” It is coverage execution:

• formulary status (preferred vs non-preferred),
• prior authorization rules,
• step therapy or documentation requirements,
• specialty pharmacy contracting.

These factors determine the practical conversion from eligible patients to treated patients.

2) Prescriber concentration and education

Because LEMS is uncommon, prescriber density is low. That compresses growth to a limited set of neurologists and neuromuscular centers. Sales performance therefore tracks:

• field coverage (specialty reps vs general neurology),
• education that accelerates diagnosis and initiation,
• patient support programs that reduce time-to-first-fill.

3) Patient persistence and tolerability

Symptomatic neurostimulant therapy has persistence risk. If adverse events or lack of perceived benefit increase discontinuations, quarterly revenue can underperform even when new starts look stable.

4) Competitive substitution

In LEMS, therapeutic substitution tends to be constrained by clinical practice patterns and safety/tolerability expectations. Still, competitors and off-label alternatives influence:

• payer willingness to approve XEPI,
• physician choice after prior therapy experience.

Net effect: XEPI competes for a small slice of eligible patients; competitive headroom is limited, so incremental penetration matters more than share shifts from mass-market competitors.

---

How does XEPI’s financial trajectory typically play out post-launch?

A small-market revenue curve

For rare neuromuscular indications, the revenue trajectory usually shows:

• early adoption plateau driven by access and prescriber ramp,
• a slower growth phase governed by diagnosis identification and persistence,
• occasional step changes from formulary wins or label/access expansions.

Key drivers of revenue variability

Quarter-to-quarter revenue swings are most often caused by:

• specialty pharmacy inventory alignment and fill timing,
• prior authorization approvals and denials,
• patient persistence changes after adverse-event cycles,
• payer contracting changes.

Pricing pressure and net-to-gross

Specialty products in US markets often face:

• rebates linked to channel volume and payer tiers,
• contract-specific net price reductions,
• tighter scrutiny as competitors establish payer familiarity.

Implication for financials: Gross-to-net dynamics can compress realized revenue even when topline demand remains stable.

---

What do the US commercialization and regulatory anchors imply?

Regulatory durability

XEPI’s ability to sustain sales is tied to:

• label stability for adult LEMS,
• safety profile management,
• continued market presence in neuromuscular prescribing ecosystems.

A stable label supports long-term contracting and payer comfort. Instability increases denial risk and delays approvals.

Specialty channel execution

US specialty products are sensitive to:

• distribution coverage,
• patient support program throughput,
• co-pay or cost-share mechanics,
• onboarding workflow for new starts.

Financial takeaway: In XEPI’s segment, execution quality can matter as much as pipeline depth because the market is too small for broad miss coverage.

---

Competitive and substitution pressures: what matters financially?

Why competition is structurally different in LEMS

Compared with large disease areas, the competitive set in LEMS impacts revenue through:

• coverage gatekeeping (payer “preferred” decisions),
• physician preference after prior attempts,
• speed of access once a patient is already in the care pathway.

What to watch for in financial performance

For XEPI, the highest-signal financial indicators are:

• growth rate in treated patients (not just prescriptions),
• persistence and refill cadence,
• changes in net price and rebate intensity,
• specialty pharmacy throughput metrics (new starts and abandonment).

---

Financial trajectory framework for XEPI (what the market rewards)

1) Treated-patient growth over prescription volume

In rare disease, “prescription count” often misleads. The market rewards:

• higher conversion of eligible patients into initiated therapy,
• retention in therapy among those who start.

2) Net price discipline paired with payer acceptance

Revenue durability depends on:

• contracts that protect realized net price,
• payer acceptance that prevents denial-driven leakage.

3) Tight safety-to-access workflow

Safety events drive:

• discontinuations,
• payer re-review cycles,
• physician reluctance to re-initiate.

XEPI’s financial path is therefore linked to how quickly clinicians can document tolerability and clinical benefit.

---

Key Takeaways

• XEPI’s market is defined by adult LEMS diagnosis scarcity and specialty neurology access, not broad population demand.
• Sales growth depends on reimbursement execution, specialty pharmacy onboarding, and persistence, which drive treated-patient conversion rather than pure prescription volume.
• Financial variability typically comes from prior authorization outcomes, payer contract changes, and discontinuation/tolerability cycles.
• Competitive pressure in LEMS is less about high-volume share shifts and more about payer “gatekeeping” and physician substitution after prior therapy.

---

FAQs

1) What determines XEPI sales performance most directly?
Treated-patient conversion and persistence, shaped by payer coverage mechanics and specialty access workflow.

2) Why can revenue growth be slow in XEPI’s category?
LEMS is rare, so growth relies on incremental diagnosis and initiation within a concentrated prescriber base.

3) What drives quarterly volatility for XEPI-like products?
Prior authorization timing, specialty pharmacy fill timing, discontinuations, and contract-driven net price changes.

4) How does payer coverage affect XEPI financial outcomes?
Coverage tier placement and documentation requirements influence approvals and reduce leakage from denials.

5) What is the most financially important competitive variable in LEMS?
Physician substitution behavior plus payer preferences, which affect both access and retention.

---

References

[1] U.S. Food and Drug Administration. Drug labeling and approval information for XEPI (firdapse).